CA2320772A1 - Complexes de cyclodextrine extremement energetiques - Google Patents

Complexes de cyclodextrine extremement energetiques Download PDF

Info

Publication number
CA2320772A1
CA2320772A1 CA002320772A CA2320772A CA2320772A1 CA 2320772 A1 CA2320772 A1 CA 2320772A1 CA 002320772 A CA002320772 A CA 002320772A CA 2320772 A CA2320772 A CA 2320772A CA 2320772 A1 CA2320772 A1 CA 2320772A1
Authority
CA
Canada
Prior art keywords
drug
cyclodextrin
complexation
ring
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002320772A
Other languages
English (en)
Inventor
Thorsteinn Loftsson
Mar Masson
Einar Stefansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclops hf
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2320772A1 publication Critical patent/CA2320772A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procédés servant à augmenter l'efficacité de complexation d'un médicament avec cyclodextrine, ainsi que la disponibilité d'un médicament à la suite de l'administration d'un complexe de cyclodextrine et de médicament.
CA002320772A 1998-02-23 1999-02-16 Complexes de cyclodextrine extremement energetiques Abandoned CA2320772A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7554498P 1998-02-23 1998-02-23
US60/075,544 1998-02-23
PCT/IS1999/000003 WO1999042111A1 (fr) 1998-02-23 1999-02-16 Complexes de cyclodextrine extremement energetiques

Publications (1)

Publication Number Publication Date
CA2320772A1 true CA2320772A1 (fr) 1999-08-26

Family

ID=22126450

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002320772A Abandoned CA2320772A1 (fr) 1998-02-23 1999-02-16 Complexes de cyclodextrine extremement energetiques

Country Status (7)

Country Link
EP (1) EP1067942A1 (fr)
JP (1) JP2003522207A (fr)
AU (1) AU759280C (fr)
CA (1) CA2320772A1 (fr)
IS (1) IS5572A (fr)
NZ (1) NZ505951A (fr)
WO (1) WO1999042111A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7937500A (en) * 1999-10-27 2001-05-08 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
AU4866001A (en) * 2000-03-28 2001-10-08 Farmarc Nederland Bv Alprazolam inclusion complexes and pharmaceutical compositions thereof
IL159415A0 (en) 2001-06-18 2004-06-01 Noven Pharma Enhanced drug delivery in transdermal systems
US6805878B2 (en) 2001-09-13 2004-10-19 Noven Pharmaceuticals, Inc. Transdermal administration of ACE inhibitors
WO2003022270A1 (fr) * 2001-09-13 2003-03-20 Noven Pharmaceuticals, Inc. Administration transcutanee d'un ester d'enalapril
DE60319221T2 (de) * 2002-06-13 2009-03-05 Novartis Ag Quaternisierte ammoniumcyclodextrinverbindungen
ES2409884T3 (es) 2003-03-28 2013-06-28 Ares Trading S.A. Formulaciones orales de cladribina
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
RU2006127432A (ru) 2003-12-31 2008-02-10 Сайдекс, Инк. (Us) Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид, полученная из единичной дозы суспензии
GB0400804D0 (en) * 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
PL2708225T3 (pl) 2004-04-23 2019-07-31 Cydex Pharmaceuticals, Inc. Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
DK1945228T4 (da) 2005-10-26 2015-01-12 Cydex Pharmaceuticals Inc Sulfoalkyl-ether-cyclodextrin-sammensætninger og fremgangsmåder til fremstilling deraf
MY150649A (en) * 2006-10-20 2014-02-14 Icos Corp Compositions of chk1 inhibitors
CA2669705A1 (fr) * 2006-11-21 2008-05-29 Novartis Ag Formulation parenterale stable contenant un inhibiteur de vsr d'une structure de benzodiazepine
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
EP2106786A1 (fr) 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Préparation pharmaceutique comprenant du cyclodextrine permethylé
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010076112A2 (fr) 2008-12-29 2010-07-08 Unilever Plc Produits alimentaires enrichis en méthylxanthines
WO2010132711A1 (fr) 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Compositions pharmaceutiques comprenant des dérivés de prasugrel et de cyclodextrine, leurs procédés de préparation et méthodes d'utilisation
CA2798911C (fr) 2010-05-19 2018-07-03 Unilever Plc Theobromine pour l'elevation de hdl-cholesterol
EP2678320B1 (fr) 2011-02-23 2018-09-19 Coeruleus Ltd. Complexes de flumazénil, compositions les comprenant et leurs utilisations
DK3702374T3 (da) 2012-02-15 2022-06-27 Cydex Pharmaceuticals Inc Fremsgangsmåde til fremstilling for cyclodextrin-derivater
HK1211311A1 (en) 2012-02-28 2016-05-20 锡德克斯药物公司 Alkylated cyclodextrin compositions and processes for preparing and using the same
WO2014066274A1 (fr) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Compositions de cyclodextrine alkylée et procédés de préparation et d'utilisation de celles-ci
WO2014075935A1 (fr) 2012-11-15 2014-05-22 Sapiotec Gmbh Complexe de delphinidine en tant que principe actif antiphlogistique ou immunosuppresseur
US9949947B2 (en) 2012-12-11 2018-04-24 Sapiotec Gmbh Delphinidin for combating melanoma cells
JP6914188B2 (ja) 2014-08-22 2021-08-04 サイデックス・ファーマシューティカルズ・インコーポレイテッド 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation

Also Published As

Publication number Publication date
AU2638599A (en) 1999-09-06
WO1999042111A1 (fr) 1999-08-26
EP1067942A1 (fr) 2001-01-17
NZ505951A (en) 2003-02-28
AU759280B2 (en) 2003-04-10
IS5572A (is) 2000-08-16
AU759280C (en) 2004-01-22
JP2003522207A (ja) 2003-07-22

Similar Documents

Publication Publication Date Title
AU759280C (en) High-energy cyclodextrin complexes
US6699849B1 (en) Cyclodextrin complexes of benzodiazepines
Loftsson et al. Self‐association and cyclodextrin solubilization of drugs
JP3579060B2 (ja) アリール―複素環式化合物塩の包接錯体
AU565966B2 (en) Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US6407079B1 (en) Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US20050222086A1 (en) Alprazolam inclusion complexes and pharmaceutical composition thereof
US6468989B1 (en) Gel compositions containing metronidazole
JP4439596B2 (ja) 長期の貯蔵寿命を有する、極性薬物又は極性プロドラッグを含有する医薬組成物、及びその製造方法
TWI232752B (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and composition and pharmaceutical composition comprising the same
Sigurðoardóttir et al. The effect of polyvinylpyrrolidone on cyclodextrin complexation of hydrocortisone and its diffusion through hairless mouse skin
HU206381B (en) Process for producing new complexes consisting of gamma-cyclodextrin ether or mixed ether and active ingredient, as well as pharmaceutical compositions comprising such complexes
Das et al. Utility of Sulfobutyl Ether β-Cyclodextrin Inclusion Complexes in Drug Delivery: A Review.
JP3007312B2 (ja) 包接複合体を製造するための塩の選別法
Dollo et al. Inclusion complexation of amide-typed local anaesthetics with β-cyclodextrin and its derivatives. I. Physicochemical characterization
Kratz et al. Preparation, characterization, and in vitro intestinal permeability evaluation of thalidomide–hydroxypropyl-β-cyclodextrin complexes
Castelli et al. Effect of the complexation of some nonsteroidal anti-inflammatory drugs with β-cyclodextrin on the interaction with phosphatidylcholine liposomes
Ramos-Martínez et al. Use of cyclodextrins as excipients in pharmaceutical products: why not in extemporaneous preparations?
Loftsson et al. Improved acitretin delivery through hairless mouse skin by cyclodextrin complexation
Loftsson et al. Drug solubilization and stabilization by cyclodextrin drug carriers
JPH07165616A (ja) シクロデキストリンの複合組成物及び複合化法
Skiba et al. Pharmacokinetic study of an oral piroxicam formulation containing different molar ratios of β-cyclodextrins
Kalaiselvan et al. Multicomponent system of albendazole with cyclodextrins and hydroxyacids
Van Doorne et al. Interactions between cyclodextrins and some antimycotic imidazole derivatives: Studies on solubility and antimicrobial activity
Panda et al. Cyclodextrin as carrier for drug delivery systems

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead